IL236428A0 - Engineered proteins with a modified ankyrin that bind to platelet-derived growth factor - Google Patents
Engineered proteins with a modified ankyrin that bind to platelet-derived growth factorInfo
- Publication number
- IL236428A0 IL236428A0 IL236428A IL23642814A IL236428A0 IL 236428 A0 IL236428 A0 IL 236428A0 IL 236428 A IL236428 A IL 236428A IL 23642814 A IL23642814 A IL 23642814A IL 236428 A0 IL236428 A0 IL 236428A0
- Authority
- IL
- Israel
- Prior art keywords
- platelet
- growth factor
- derived growth
- ankyrin repeat
- repeat proteins
- Prior art date
Links
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 title 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 title 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174020 | 2012-06-28 | ||
| PCT/EP2013/063488 WO2014001442A1 (en) | 2012-06-28 | 2013-06-27 | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL236428A0 true IL236428A0 (en) | 2015-02-26 |
Family
ID=48699826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236428A IL236428A0 (en) | 2012-06-28 | 2014-12-24 | Engineered proteins with a modified ankyrin that bind to platelet-derived growth factor |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9163070B2 (enExample) |
| EP (1) | EP2867360B1 (enExample) |
| JP (1) | JP2015522576A (enExample) |
| KR (1) | KR20150023957A (enExample) |
| CN (1) | CN104508129A (enExample) |
| AU (1) | AU2013283296A1 (enExample) |
| BR (1) | BR112014032316A2 (enExample) |
| CA (1) | CA2877584A1 (enExample) |
| HK (1) | HK1209156A1 (enExample) |
| IL (1) | IL236428A0 (enExample) |
| IN (1) | IN2014MN02522A (enExample) |
| MX (1) | MX2014015825A (enExample) |
| RU (1) | RU2014150224A (enExample) |
| SG (1) | SG11201408196RA (enExample) |
| WO (1) | WO2014001442A1 (enExample) |
| ZA (1) | ZA201408872B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| CN103459415B (zh) * | 2010-11-26 | 2021-04-09 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| EP3646880A1 (en) | 2012-05-07 | 2020-05-06 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| US10665324B2 (en) | 2014-07-07 | 2020-05-26 | Yeda Research And Development Co. Ltd. | Method of computational protein design |
| US20170226158A1 (en) * | 2014-08-11 | 2017-08-10 | Medimmune Limited | Intracellular antigen binding |
| CA2963723A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-pdgf-b antibodies and methods of use |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| CN107074941A (zh) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 双特异性抗体和用于眼科学的方法 |
| SG11201703458UA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
| AU2016240220B2 (en) | 2015-04-02 | 2019-11-21 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| US10283384B2 (en) * | 2015-04-27 | 2019-05-07 | Taiwan Semiconductor Manufacturing Co., Ltd. | Method for etching etch layer and wafer etching apparatus |
| ES2953516T3 (es) | 2016-09-22 | 2023-11-14 | Molecular Partners Ag | Proteínas de unión recombinantes y su uso |
| US10037890B2 (en) * | 2016-10-11 | 2018-07-31 | Lam Research Corporation | Method for selectively etching with reduced aspect ratio dependence |
| US11127483B2 (en) | 2017-03-07 | 2021-09-21 | Igc Bio, Inc. | Computational pipeline for antibody modeling and design |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| CN111886338A (zh) | 2018-03-22 | 2020-11-03 | 柏林夏瑞蒂医科大学 | Crispr相关蛋白反应性t细胞免疫 |
| WO2019238966A1 (en) | 2018-06-15 | 2019-12-19 | Universität Bern | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES |
| BR112021005670A2 (pt) | 2018-10-08 | 2021-06-22 | Universität Zürich | polipeptídeos tetraméricos de ligação a her2 |
| WO2020104627A1 (en) | 2018-11-21 | 2020-05-28 | Universität Zürich | Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction |
| EP3677911A3 (en) | 2019-01-03 | 2020-07-29 | Universität Basel | Use of non-agonist ligands for suppression of metastasis |
| US20220088144A1 (en) | 2019-01-11 | 2022-03-24 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery |
| US20220178926A1 (en) | 2019-04-10 | 2022-06-09 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
| CA3139051A1 (en) | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| US20220242973A1 (en) * | 2019-06-04 | 2022-08-04 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| CA3139041A1 (en) * | 2019-06-04 | 2020-12-10 | Christian REICHEN | Recombinant 4-1bb binding proteins and their use |
| WO2021044050A1 (en) | 2019-09-05 | 2021-03-11 | Genome Biologics Ug | Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure |
| WO2021116462A1 (en) | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| WO2021122813A1 (en) | 2019-12-16 | 2021-06-24 | Universität Basel | Angiogenesis promoting agents for prevention of metastatic cancer |
| WO2021176008A1 (en) | 2020-03-04 | 2021-09-10 | Cornell University | Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer |
| US20230151118A1 (en) | 2020-04-06 | 2023-05-18 | Universität Zürich | Artc1 ligands for cancer treatment |
| TW202208404A (zh) | 2020-05-06 | 2022-03-01 | 瑞士商分子組合公司 | 新穎錨蛋白重複結合蛋白質及其用途 |
| BR112022023049A2 (pt) | 2020-05-14 | 2022-12-20 | Molecular Partners Ag | Proteínas multiespecíficas |
| WO2021239844A1 (en) | 2020-05-27 | 2021-12-02 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes |
| WO2021239999A1 (en) | 2020-05-28 | 2021-12-02 | Universität Zürich | Il-12 pd-l1 ligand fusion protein |
| AU2021327147A1 (en) | 2020-08-18 | 2023-04-06 | Universität Zürich | A CD25-biased anti-IL-2 antibody |
| JP2023554351A (ja) | 2020-12-16 | 2023-12-27 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規の徐放性プロドラッグ |
| US20240310378A1 (en) | 2021-02-11 | 2024-09-19 | Universität Zürich | Use of markers found on lymph node metastatic samples for the prognosis of breast cancer |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| JP2024509904A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ |
| AU2022231913A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| CA3227299A1 (en) | 2021-08-05 | 2023-02-09 | Immunos Therapeutics Ag | Pharmaceutical compositions comprising hla fusion proteins |
| KR20240045260A (ko) | 2021-08-05 | 2024-04-05 | 이뮤노스 테라퓨틱스 아게 | Hla 융합 단백질을 포함하는 복합 치료제 |
| WO2023021006A1 (en) | 2021-08-16 | 2023-02-23 | Universität Zürich | Il-1 targeting agents for treatment of pitiyriasis rubra pilaris |
| WO2023036849A1 (en) | 2021-09-07 | 2023-03-16 | ETH Zürich | Identifying and predicting future coronavirus variants |
| EP4163380A1 (en) | 2021-10-08 | 2023-04-12 | ETH Zurich | Device and method for manipulation of extracellular vesicles |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| WO2023110942A1 (en) | 2021-12-14 | 2023-06-22 | Charité-Universitätsmedizin Berlin | Prevention of impaired fracture healing |
| EP4260907A1 (en) | 2022-04-11 | 2023-10-18 | Universität Zürich | Agents for treatment of endometriosis and other benign gynecological neoplasms |
| WO2024002914A1 (en) | 2022-06-27 | 2024-01-04 | Charité-Universitätsmedizin Berlin | Prediction of, and composition to improve, tendon healing |
| CN119731200A (zh) | 2022-08-01 | 2025-03-28 | 分子合作伙伴股份公司 | 经电荷修饰设计的重复结构域及其用途 |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024133013A1 (en) | 2022-12-19 | 2024-06-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Means and methods to target endogenous condensates |
| AU2024217729A1 (en) | 2023-02-08 | 2025-08-21 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2025008519A1 (en) | 2023-07-05 | 2025-01-09 | Universität Bern | Il-1ra blockers for treatment and prevention of sepsis |
| WO2025021293A1 (en) | 2023-07-25 | 2025-01-30 | Universität Zürich | Disruption of rbr1 expression in plant cells |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025202503A1 (en) | 2024-03-28 | 2025-10-02 | Universität Zürich | Extracellular vesicles carrying cancer specific splice variants |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5094941A (en) * | 1987-12-31 | 1992-03-10 | Zymogenetics, Inc. | Monoclonal antibodies to PDGF |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| DE69834032T2 (de) | 1997-04-23 | 2006-12-07 | Universität Zürich | Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren |
| ES2280131T3 (es) | 1998-12-02 | 2007-09-01 | Adnexus Therapeutics, Inc. | Fusiones de adn-proteina y utilizaciones de las mismas. |
| JP5291279B2 (ja) * | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| WO2003025019A1 (en) * | 2001-09-20 | 2003-03-27 | Alexion Pharmaceuticals, Inc. | Anti-pdgf antibodies and methods for producing engineered antibodies |
| SI1660057T1 (sl) * | 2003-08-27 | 2012-10-30 | Ophthotech Corp | Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti |
| BRPI0517834A (pt) * | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
| WO2006129828A2 (en) * | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Target substance capturing molecule |
| DE602006010386D1 (en) | 2005-07-08 | 2009-12-24 | Univ Zuerich | Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden |
| WO2007103515A2 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| UY31504A1 (es) | 2007-11-30 | 2009-07-17 | Construcciones de union de antigenos | |
| WO2009100990A1 (en) * | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Process for the production of a peptide |
| EP2263088A2 (en) * | 2008-03-19 | 2010-12-22 | Institut Pasteur | Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use |
| WO2010060748A1 (en) * | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| CN103459415B (zh) * | 2010-11-26 | 2021-04-09 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| WO2012149439A2 (en) * | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
-
2013
- 2013-06-27 BR BR112014032316A patent/BR112014032316A2/pt not_active IP Right Cessation
- 2013-06-27 CN CN201380034192.1A patent/CN104508129A/zh active Pending
- 2013-06-27 KR KR20157002327A patent/KR20150023957A/ko not_active Withdrawn
- 2013-06-27 RU RU2014150224A patent/RU2014150224A/ru not_active Application Discontinuation
- 2013-06-27 AU AU2013283296A patent/AU2013283296A1/en not_active Abandoned
- 2013-06-27 CA CA2877584A patent/CA2877584A1/en not_active Abandoned
- 2013-06-27 JP JP2015519089A patent/JP2015522576A/ja active Pending
- 2013-06-27 HK HK15109777.3A patent/HK1209156A1/xx unknown
- 2013-06-27 WO PCT/EP2013/063488 patent/WO2014001442A1/en not_active Ceased
- 2013-06-27 US US13/928,973 patent/US9163070B2/en active Active
- 2013-06-27 EP EP13731809.3A patent/EP2867360B1/en active Active
- 2013-06-27 SG SG11201408196RA patent/SG11201408196RA/en unknown
- 2013-06-27 MX MX2014015825A patent/MX2014015825A/es unknown
-
2014
- 2014-12-03 ZA ZA2014/08872A patent/ZA201408872B/en unknown
- 2014-12-11 IN IN2522MUN2014 patent/IN2014MN02522A/en unknown
- 2014-12-24 IL IL236428A patent/IL236428A0/en unknown
-
2015
- 2015-09-08 US US14/847,403 patent/US20150368302A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201408196RA (en) | 2015-03-30 |
| MX2014015825A (es) | 2015-08-10 |
| ZA201408872B (en) | 2016-05-25 |
| BR112014032316A2 (pt) | 2017-06-27 |
| US20140005125A1 (en) | 2014-01-02 |
| JP2015522576A (ja) | 2015-08-06 |
| CN104508129A (zh) | 2015-04-08 |
| CA2877584A1 (en) | 2014-01-03 |
| KR20150023957A (ko) | 2015-03-05 |
| RU2014150224A (ru) | 2016-08-20 |
| US20150368302A1 (en) | 2015-12-24 |
| EP2867360A1 (en) | 2015-05-06 |
| US9163070B2 (en) | 2015-10-20 |
| HK1209156A1 (en) | 2016-03-24 |
| WO2014001442A1 (en) | 2014-01-03 |
| EP2867360B1 (en) | 2019-05-08 |
| AU2013283296A1 (en) | 2015-02-05 |
| IN2014MN02522A (enExample) | 2015-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236428A0 (en) | Engineered proteins with a modified ankyrin that bind to platelet-derived growth factor | |
| IL240838A0 (en) | Anti-3–lag binding proteins | |
| SG10201607962RA (en) | Artificial nucleic acid molecules | |
| AP2015008266A0 (en) | 1L-18 binding molecules | |
| IL235128B (en) | Preparation of a sample of nucleic acids | |
| IL239219A0 (en) | bcma antigen binding proteins | |
| IL222323A0 (en) | Tnf - alpha binding proteins | |
| ZA201500203B (en) | Transposition-mediated identification of specific binding or functional proteins | |
| EP2932375A4 (en) | ADAPTATION OF OPPORTUNITY IN CONTEXT | |
| ZA201404481B (en) | Il-1 binding proteins | |
| SG11201504249XA (en) | Methods to control protein heterogeneity | |
| PL2914287T3 (pl) | Elementy wiążące się z il-1 beta | |
| IL237854A0 (en) | Proteins that bind her3 antibody that binds to the beta-herpin of her3 | |
| IL235134B (en) | il–6 binding molecules | |
| PL2851083T3 (pl) | Kompozycja białkowa odporna na sterylizację promieniowaniem | |
| EP2911694A4 (en) | ANTI-INFECTIOUS BINDING PROTEINS THAT BIND TO AIP2 | |
| GB201418608D0 (en) | Peridinin-chlorophyll binding proteins | |
| EP2999710A4 (en) | Peptides binding to parallel-stranded g-quadruplexes | |
| GB201200563D0 (en) | Binding molecule | |
| SG10201704145RA (en) | Biotinylated protein | |
| GB201213672D0 (en) | Protein | |
| GB201211286D0 (en) | Novel biological factor | |
| GB201215901D0 (en) | Protein modification | |
| GB201214293D0 (en) | Binding surfaces | |
| GB201202569D0 (en) | Compositions for binding to amyloid proteins |